Ferring Pharmaceuticals
Avenue de Rhodanie 60
Lausanne
CH 1007
United States
Tel: 41-21-614-2772
Fax: 41-21-614-2773
Website: http://www.ferring.com/
226 articles about Ferring Pharmaceuticals
-
Phase 4 Study Evaluating Use of ADSTILADRIN® (nadofaragene firadenovec-vncg) in Real-World Setting
1/24/2024
Ferring Pharmaceuticals announced today it is presenting the methodology for the ADSTILADRIN in BLadder cancEr (ABLE-41) Real World Evidence (RWE) study at the 20th Annual American Society of Clinical Oncologists Genitourinary Cancers Symposium (ASCO GU).
-
Ferring Announces Full Availability of ADSTILADRIN® (nadofaragene firadenovec-vncg) in the U.S.
1/16/2024
Ferring Pharmaceuticals announced that ADSTILADRIN® is now fully available across the U.S. for healthcare providers to prescribe for their adult patients with high-risk Bacillus Calmette-Guérin -unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.
-
Ferring and PharmaBiome Enter Into a New Microbiome R&D Collaboration and Exclusive Licensing Agreement
12/11/2023
Ferring Pharmaceuticals and Zürich-based microbiome translation company PharmaBiome are announcing a research and development collaboration to drive forward new microbiome-based biotherapeutics in the field of gastroenterology.
-
New Data Show Durable Response Following Treatment with ADSTILADRIN® (nadofaragene firadenovec-vncg)
11/29/2023
Ferring Pharmaceuticals today announced the presentation of new 36-month follow-up data from the Phase 3 study at the 24th Annual Meeting of the Society of Urologic Oncology (SUO) demonstrating a sustained durability of response with ADSTILADRIN® (nadofaragene firadenovec-vncg) in adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors (±Ta/T1).
-
ACG 2023 Presentations for REBYOTA® (fecal microbiota, live – jslm) Explore Association Between Gut Microbiome Composition and Health-Related Quality of Life and Evaluate Efficacy and Safety in Older Patients With Comorbidities
10/23/2023
Ferring Pharmaceuticals announced two poster presentations at the American College of Gastroenterology’s 2023 Annual Scientific Meeting for REBYOTA®, the first and only single-dose microbiome-based treatment approved by the U.S. Food and Drug Administration for the prevention of recurrent Clostridioides difficile infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
-
ASRM Announces Historic $5 Million Endowment From Ferring Pharmaceuticals
10/16/2023
The American Society for Reproductive Medicine and Ferring Pharmaceuticals announced a historic $5 million endowment from Ferring to ASRM.
-
More Real-World Data and New Analyses of Data for REBYOTA® (fecal microbiota, live – jslm) Presented at IDWeek 2023
10/11/2023
Ferring Pharmaceuticals today announced four poster presentations at Infectious Disease Week (IDWeek) 2023 for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose microbiome-based treatment approved by the U.S. Food and Drug Administration (FDA) for the prevention of recurrent Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
-
Ferring to Present New Data Analyses at ACG 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
10/3/2023
Ferring Pharmaceuticals today announced it will present two analyses of data for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose, FDA approved microbiome-based treatment to prevent recurrent Clostridioides difficile (C. diff) infection after antibiotic treatment.
-
Bladder Cancer Advocacy Network Announces Exclusive National Presenting Sponsorship by Ferring Pharmaceuticals for 2024 Walks to End Bladder Cancer
10/2/2023
The Bladder Cancer Advocacy Network announced its exclusive partnership with Ferring Pharmaceuticals as the National Presenting Sponsor for its 2024 Walks to End Bladder Cancer.
-
Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection
9/21/2023
Ferring to Present New Data Analyses at IDWeek 2023 for REBYOTA ® (fecal microbiota, live – jslm), the First and Only Single-Dose, FDA Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection.
-
First Bladder Cancer Patient Dosed with Commercially Available Intravesical Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg)
9/12/2023
Ferring Pharmaceuticals announced the first patient in the United States with high-risk Bacillus Calmette-Guérin -unresponsive non-muscle invasive bladder cancer was dosed with the commercially available intravesical gene therapy ADSTILADRIN® as part of the ADSTILADRIN Early Experience Program announced earlier this year.
-
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
8/24/2023
Royalty Pharma plc and Ferring Pharmaceuticals announced that Royalty Pharma has acquired a synthetic royalty on US net sales of Ferring’s Adstiladrin® for up to US $500 million comprised of an upfront payment of US $300 million and a US $200 million milestone payment.
-
The world's largest buyer of biopharma royalties is paying $300 million up front and $200 million in milestone payments for Ferring Pharmaceuticals’ FDA-approved bladder cancer drug Adstiladrin.
-
Largest Integrated Safety Analysis From Five Prospective Clinical Trials for REBYOTA® (fecal microbiota, live – jslm) Published in Therapeutic Advances in Gastroenterology
7/11/2023
Ferring Pharmaceuticals today announced that Therapeutic Advances in Gastroenterology has published an integrated safety analysis from five prospective clinical trials for REBYOTA® (fecal microbiota, live – jslm), the first and only single-dose, FDA approved microbiome-based treatment to prevent recurrent C. diff infection after antibiotic treatment.
-
Ferring Pharmaceuticals appoints new Executive Chairman among key changes to Board of Directors
6/22/2023
Ferring Pharmaceuticals announced that Jean-Frédéric Paulsen has been appointed Executive Chairman of the Ferring Group, as it enters a new phase of growth following the approval of two innovative medicines by the US Food and Drug Administration.
-
Ferring Pharmaceuticals successfully increases its second Swiss Franc Bond offering by CHF 80 million
6/16/2023
Ad hoc announcement pursuant to Art. 53 LR Ferring Pharmaceuticals announced the successful increase of its second Swiss Franc Bond offering by CHF 80 million.
-
Ferring Pharmaceuticals Receives U.S. FDA Approval of Drug Substance Manufacturing Scale-up Process for Gene Therapy ADSTILADRIN® (nadofaragene firadenovec-vncg)
6/12/2023
Ferring Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved a Prior-Approval Supplement (PAS) to the Biologics License Application (BLA) for the novel intravesical gene-therapy ADSTILADRIN® (nadofaragene firadenovec-vncg), enabling the Company to scale-up its drug substance manufacturing process at FinVector Oy located in Kuopio, Finland.
-
Ferring Announces Positive Topline Phase 3 Results for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
5/26/2023
Ferring Pharmaceuticals announced that its clinical development partner, Seikagaku Corporation, achieved positive topline results for its registrational Phase 3 clinical trial of SI-6603, an investigational treatment for lumbar disc herniation.
-
Ferring to Present Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, at DDW 2023
4/18/2023
Ferring to Present Analyses of Data for REBYOTA ™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, at DDW 2023.
-
Ferring and BioInnovation Institute enter new strategic collaboration to accelerate innovation in women’s health
4/18/2023
Ferring Pharmaceuticals and BioInnovation announce a new strategic collaboration to accelerate innovation in women’s health.